ADT in Men: HPG Axis Suppression Mechanisms, Bone Pathology, and Safe Supplementation

Androgen deprivation therapy (ADT) is the cornerstone of systemic prostate cancer treatment and represents one of the most hormonally disruptive medical interventions in men's health. The primary goal — suppression of circulating testosterone to castrate levels (below 50 ng/dL) — is achieved through two distinct mechanistic routes: GnRH agonists (leuprolide, goserelin) and GnRH antagonists (degarelix, relugolix). Beyond the intended testosterone suppression, ADT produces a cascade of secondary effects on bone mineral density, cardiovascular physiology, metabolic function, and cognitive health through the absence of androgen signaling in non-prostate tissues. Supplement strategy during ADT must be sharply constrained to interventions that address these secondary effects without interfering with the central androgen suppression goal. This requires understanding not only the mechanisms of harm (what specific supplements do to the HPG axis) but also the mechanisms of ADT's medically necessary toxicities. This guide and Helian's After protocol are built on those distinctions. Oncologist consultation is mandatory before any supplement addition.

GnRH agonist versus antagonist: HPG axis suppression mechanisms

GnRH agonists (leuprolide, goserelin) produce testosterone suppression through receptor desensitization rather than direct blockade. Upon initial injection, continuous GnRH receptor stimulation (bypassing normal pulsatility) causes a paradoxical testosterone surge lasting 1 to 2 weeks — the "flare" phenomenon — as pituitary gonadotrophs respond to persistent stimulation. This is followed by GnRH receptor downregulation and pituitary gonadotroph desensitization, eliminating LH and FSH pulsatility and achieving castrate testosterone levels within 2 to 4 weeks. The initial flare carries clinical risk in patients with spinal metastases and requires co-administration of an anti-androgen (bicalutamide) for 4 to 6 weeks. GnRH antagonists (degarelix, relugolix) achieve testosterone suppression via direct competitive blockade at pituitary GnRH receptors, without the initial agonist flare. Testosterone suppression occurs within 3 days. Relugolix (oral GnRH antagonist) demonstrated significantly reduced cardiovascular events versus leuprolide in the HERO trial — potentially because it avoids the testosterone surge and has a shorter T1/2 allowing faster recovery if stopped.

ADT bone loss: RANK-L upregulation and the skeletal consequences of androgen deprivation

Testosterone is a critical regulator of bone homeostasis in men via two pathways: direct AR signaling in osteoblasts (promoting bone formation) and indirect via aromatization to estradiol (inhibiting osteoclast activity through ER-alpha in bone). ADT abolishes both pathways simultaneously. The mechanistic driver of ADT-induced bone loss is RANK-L (receptor activator of NF-kB ligand) upregulation. Osteoblasts and stromal cells express RANK-L, which binds RANK receptors on osteoclast precursors, driving osteoclastogenesis and osteoclast activation. Testosterone normally suppresses RANK-L expression through AR signaling in osteoblasts; castrate testosterone levels remove this inhibition, leading to RANK-L overexpression, osteoclast hyperactivation, and bone resorption exceeding formation. ADT-induced bone loss proceeds at 3 to 5 percent per year. Vitamin D3 (1,000 to 2,000 IU) and calcium address both ends of the remodeling cycle: vitamin D ensures adequate calcium absorption and maintains osteoblast function; calcium provides the mineral substrate for bone matrix mineralization. In men with high fracture risk, oncologists may also prescribe denosumab (a RANK-L antibody) — supplements are adjunctive to, not a replacement for, these medical interventions.

AR-V7 and castration-resistant prostate cancer: why androgen pathway supplements are absolutely contraindicated

The transition from hormone-sensitive to castration-resistant prostate cancer (CRPC) occurs when tumor cells develop mechanisms to maintain androgen receptor (AR) signaling despite castrate testosterone levels. The androgen receptor splice variant AR-V7 is the dominant mechanism — a constitutively active truncated AR lacking the ligand-binding domain that drives transcription of AR target genes (PSA, TMPRSS2) independent of testosterone or DHT. CRPC cells can also synthesize intra-tumoral androgens from DHEA and adrenal precursors via upregulated CYP17A1 and HSD3B1 pathways. Supplements that raise serum testosterone — tongkat ali (via LH amplification), shilajit, fadogia (via testicular stimulation) — provide substrate for intratumoral androgen synthesis and, in the pre-AR-V7 stage, directly stimulate AR signaling in tumor cells — counteracting the entire mechanism of ADT. The clinical rule is absolute: no testosterone-pathway supplements during ADT, and any hormonal support after ADT completion requires oncological clearance based on PSA trajectory, imaging, and disease status.

Safe supplement rationale during ADT: omega-3 and CoQ10 for cardiovascular and energy effects

ADT significantly increases cardiovascular risk: within the first year, testosterone suppression alters lipid profiles (increased LDL, decreased HDL), promotes insulin resistance, increases adipose tissue, and can cause QT prolongation (relevant to GnRH agonists). Omega-3 (EPA + DHA, 2 to 4g/day) has the most direct cardiovascular risk reduction evidence in the post-ADT context — reducing triglycerides, inflammatory markers, and through PPAR-alpha signaling, improving cardiomyocyte fat oxidation. CoQ10 (100 to 200mg ubiquinol) addresses the fatigue that ADT produces through mitochondrial mechanisms — testosterone normally upregulates mitochondrial biogenesis (PGC-1alpha pathway), and its absence reduces cellular energy production capacity. CoQ10 partially compensates via direct ETC support. Neither omega-3 nor CoQ10 engages testosterone synthesis or AR signaling pathways. Magnesium supports sleep (ADT-induced hot flashes disrupt sleep architecture) through GABA-ergic mechanisms. These three form the ADT-compatible supplement core, with vitamin D and calcium as the bone-protective foundation.

The bottom line

ADT supplement strategy requires the clearest mechanistic thinking of any hormonal context in men's health. The absolute contraindications — tongkat ali (LH amplification mechanism), fadogia (testicular stimulation), shilajit, high-dose DHEA, and any testosterone booster — are not precautionary; they are mechanistically antagonistic to ADT's therapeutic mechanism and in CRPC risk providing intratumoral androgen substrate. The safe interventions address ADT's secondary pathology: vitamin D and calcium for RANK-L-driven bone loss; omega-3 for ADT-associated cardiovascular risk; CoQ10 for mitochondrial energy deficit; magnesium for sleep disruption from hot flashes. Helian's After protocol reflects this distinction precisely. Every supplement addition requires oncologist review.

Frequently Asked Questions

What is the mechanism by which the GnRH agonist flare increases prostate cancer risk acutely?

The initial 1 to 2 week testosterone surge from GnRH agonist initiation transiently stimulates AR signaling in remaining tumor cells, potentially stimulating proliferation and, in patients with spinal metastases, increasing the risk of cord compression through tumor growth and edema. Anti-androgen co-therapy (bicalutamide 50mg/day starting 7 to 14 days before agonist injection) competitively blocks AR at the ligand-binding domain, attenuating the flare's tumor-stimulating effect while still allowing agonist-mediated pituitary desensitization to proceed.

How does AR-V7 status affect supplement decisions in CRPC?

AR-V7 positivity indicates tumor cells are driving AR signaling constitutively — independent of circulating testosterone. Even in this context, supplements that raise testosterone may support AR-V7 negative tumor subpopulations that remain testosterone-responsive (clonal heterogeneity), and they provide intratumoral androgen synthesis substrate through CYP17A1 upregulated in CRPC. The oncological principle remains: no androgen-pathway supplementation until clear disease-free status is established and the treating oncologist specifically approves.

Is DHEA supplementation ever appropriate during or after ADT?

DHEA is an adrenal androgen precursor that is directly converted to testosterone and DHT in peripheral tissues. During ADT, DHEA supplementation provides intratumoral androgen synthesis substrate in a disease context where even low-level androgen availability drives progression — it is contraindicated for this reason. After ADT completion in disease-free patients, the appropriateness of DHEA depends on oncological assessment, PSA status, imaging findings, and time since treatment. This is not a supplement to add independently; it requires explicit oncological clearance.

Can any testosterone-supporting supplements ever be reintroduced after ADT?

Potentially, in specific clinical contexts. Oligometastatic patients achieving undetectable PSA and radiographic complete response may eventually be candidates for ADT discontinuation, after which testosterone recovery becomes applicable — but only under close oncological monitoring with predefined PSA thresholds for re-initiation. The common denominator: these are clinical decisions made by the oncology team based on disease-specific data, not supplement choices made independently.

Build your Cancer / ADT protocol.

Helian builds a circadian-timed supplement protocol for your exact hormonal profile — AM and PM windows, evidence-based dosages.

See your Cancer / ADT profile →

← All guides